Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prestige Consumer Healthcare (PBH) Amortization of Deferred Charges (2016 - 2025)

Historic Amortization of Deferred Charges for Prestige Consumer Healthcare (PBH) over the last 17 years, with Q4 2025 value amounting to $452000.0.

  • Prestige Consumer Healthcare's Amortization of Deferred Charges rose 414.75% to $452000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $1.8 million, marking a year-over-year decrease of 3713.78%. This contributed to the annual value of $1.8 million for FY2025, which is 6652.67% down from last year.
  • According to the latest figures from Q4 2025, Prestige Consumer Healthcare's Amortization of Deferred Charges is $452000.0, which was up 414.75% from $447000.0 recorded in Q3 2025.
  • Prestige Consumer Healthcare's Amortization of Deferred Charges' 5-year high stood at $1.8 million during Q1 2023, with a 5-year trough of $428000.0 in Q3 2024.
  • Its 5-year average for Amortization of Deferred Charges is $916950.0, with a median of $821500.0 in 2022.
  • In the last 5 years, Prestige Consumer Healthcare's Amortization of Deferred Charges surged by 11136.71% in 2021 and then tumbled by 7107.0% in 2025.
  • Quarter analysis of 5 years shows Prestige Consumer Healthcare's Amortization of Deferred Charges stood at $1.4 million in 2021, then tumbled by 40.77% to $815000.0 in 2022, then soared by 74.72% to $1.4 million in 2023, then tumbled by 69.52% to $434000.0 in 2024, then rose by 4.15% to $452000.0 in 2025.
  • Its Amortization of Deferred Charges stands at $452000.0 for Q4 2025, versus $447000.0 for Q3 2025 and $442000.0 for Q2 2025.